Table 4 Pharmacokinetic parameters for recaticimab
| Â | 75 mg Q4W (N=10) | 150 mg Q4W (N=17) | 150 mg Q8W (N=10) | 300 mg Q8W (N=15) | 300 mg Q12W (N=10) | 450 mg Q12W (N=20) |
|---|---|---|---|---|---|---|
After first dose | ||||||
 Tmax (day) | 9.0 (3.9, 14.0) | 9.0 (6.0, 20.9) | 7.0 (4.0, 14.0) | 8.9 (2.0, 22.0) | 9.0 (6.0, 21.0) | 6.0 (3.9, 22.0) |
 Cmax (μg/mL) | 5.7 (43.7%) | 12.1 (35.9%) | 9.8 (41.0%) | 31.4 (23.6%) | 28.4 (44.0%) | 43.2 (39.9%) |
 AUC0-τ (day·μg/mL) | 126 (45%) | 260 (41%) | 299 (37%) | 1010 (26%) | 1180 (40%) | 1640 (46%) |
 AUClast (day·μg/mL) | 123 (42%) | 258 (37%) | 299 (37%) | 1010 (26%) | 1180 (40%) | 1640 (46%) |
After last dose | ||||||
 Tmax (day) | 7.0 (5.9, 15.0) | 7.0 (3.9, 28.0) | 7.0 (3.0, 17.0) | 7.0 (3.9, 32.2) | 7.5 (7.0, 14.0) | 7.0 (4.0, 28.9) |
 Cmax (μg/mL) | 8.7 (42.5%) | 24.4 (33.9%) | 13.0 (62.7%) | 31.7 (41.9%) | 32.0 (32.4%) | 41.1 (27.0%) |
 t1/2 (day) | 22.0 (27.3%) | 22.1 (28.0%) | 18.6 (11.8%) | 21.7 (25.7%) | 19.9 (24.8%) | 27.4 (33.2%) |
 AUC0-τ (day·μg/mL) | 197 (44%) | 553 (37%) | 411 (54%) | 1130 (47%) | 1150 (31%) | 1770 (36%) |
 AUClast (day·μg/mL) | 327 (59%) | 988 (41%) | 460 (55%) | 1310 (48%) | 1150 (31%) | 1760 (36%) |
 AUC0-∞ (day·μg/mL) | 367 (56%) | 1090 (47%) | 487 (53%) | 1430 (51%) | 1300 (38%) | 2090 (43%) |
 CL/F (L/day) | 0.4 (44.4%) | 0.3 (37.2%) | 0.4 (54%) | 0.3 (47.1%) | 0.3 (30.6%) | 0.3 (36.1%) |
 Vz/F (L) | 12.0 (33.8%) | 8.4 (30.2%) | 9.8 (56.4%) | 8.3 (50.2%) | 7.2 (18.6%) | 10.1 (28.6%) |
 Ctrough (μg/mL) | 4.8 (53.8%) | 13.4 (46.1%) | 1.9 (45.8%) | 7.5 (61.2%) | 3.0 (97.8%) | 4.0 (111.1%) |